Table 3 The characteristics of patients who discontinued treatment due to adverse effects within the first 3 months of treatment.
Olaparib (N = 131) | Niraparib (N = 50) | |
|---|---|---|
Discontinued cases | 13 (9.9%) | 5 (10.0%) |
Duration to the treatment(days) | 43 (14–77) | 27 (5–28) |
BMI | 20.8 (14.2–29.5) | 20.5 (14.3–24.9) |
Smoking | 1 (7.7%) | 1 (20.0%) |
Drinking | 0 (0.0%) | 0 (0.0%) |
DM | 1 (7.7%) | 0 (0.0%) |
Number of previous chemotherapy regimens | 2 (1–6) | 2 (1–3) |
Response to most recent treatment | ||
CR | 9 (69.2%) | 1 (20.0%) |
PR | 4 (30.8%) | 4 (80.0%) |
Maintenance for first-line chemotherapy | 3 (23.1%) | 1 (20.0%) |
Reason for termination | ||
Anemia | 2 (15.4%) | 0 (0.0%) |
Neutropenia | 1 (7.7%) | 0 (0.0%) |
Thrombocytopenia | 0 (0.0%) | 3 (60.0%) |
Fatigue, Vomiting | 8 (61.5%) | 1 (20.0%) |
Dysgeusia | 1 (7.7%) | 1 (20.0%) |
Interstitial pneumonia | 1 (7.7%) | 0 (0.0%) |
